Mahon F.-X. et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial // Lancet Oncol. 2010. Vol. 11, № 11. P. 1029–1035.
